Jaguar Health (JAGX)

Executive Summary

Jaguar Health (NASDAQ: JAGX) is a commercial-stage pharmaceutical company focused on developing and commercializing plant-based prescription medicines for gastrointestinal (GI) distress, particularly chronic diarrhea. Its lead product, Mytesi® (crofelemer), is FDA-approved for non-infectious diarrhea in HIV/AIDS patients on antiretroviral therapy. The company is leveraging crofelemer's mechanism of action to pursue additional indications, including diarrhea-predominant irritable bowel syndrome (IBS-D) and chemotherapy-induced diarrhea. Jaguar Health's subsidiary, Napo Pharmaceuticals, is advancing these programs. Despite the approved product, Jaguar Health faces significant financial and operational challenges, including low revenues and a dilutive market cap. The company's strategy centers on expanding Mytesi's label and securing partnerships to support development and commercialization. Its pipeline remains early-stage for larger indications, and the stock is highly speculative.

Upcoming Catalysts (preview)

• H2 2026FDA decision on crofelemer for IBS-D (Phase 3 data readout)25% success
• Q3 2026Potential partnership or licensing deal for crofelemer in Latin America or Asia40% success
• Q4 2026Progress update on chemotherapy-induced diarrhea (Phase 2/3 trial initiation)30% success